In the search for genes associated with disease, statistical analysis yields a key towards reproducible results. To avoid a plethora of type I errors , classical gene selection procedures strike a balance between magnitude and precision of observed effects in terms of p-values. Protecting false discovery rates recovers some power but still ranks genes according to classical p-values. In contrast, we propose a selection procedure driven by the concern to detect well-specified important alternatives. By summarizing evidence from the perspective of both the null and such an alternative hypothesis, genes line up in a substantially different order with different genes yielding powerful signals. A cutoff point for a measure of relative evidence which balances the standard p-value, p 0 , with its counterpart, p 1 , derived from the perspective of the target alternative, determines our gene selection. We find the cutoff point that maximizes an expected specific gain. This yields an optimal decision which exploits gene-specific variances and thus involves different type I and type II errors across genes. We show the dramatic impact of this alternative perspective on the detection of differentially expressed genes in hereditary breast cancer. Our analysis does not rely on parametric assumptions on the data.
INTRODUCTION
Statistical analysis of gene expression data is often aimed at detecting genes, which are differentially expressed between diseases or experimental conditions. Typically, a vast number of genes are being tested of whom only a small proportion is hoped to truly differentiate. The challenge not only lies in detecting the most promising genes without selecting too many non-differentiating genes, but also in ruling out some genes as being differentially expressed. This plays more generally in association studies such as for instance, those involving SNP's to asses the relative risk of disease. In line with classical individual test procedures, null-minded selection criteria avoid a flood of false alarms by controlling an experimentwise type I error (Hochberg and Tamhane, 1987) while accepting to sacrifice important findings due to limited power.
The philosophy behind controlling the false discovery rate (FDR) , that is the expected proportion of true null hypotheses among the rejected ones (Benjamini and Hochberg, 1995) , is one of willingness to accept a small number of type I errors relative to the number of rejected hypotheses. A range of procedures have been developed from this principle (see for example Benjamini and Hochberg, 1995; Benjamini and Yekutieli 2001; Genovese and Wasserman 2002; Storey, 2002 Storey, & 2003 Storey and Tibshirani, 2003; Wacholder, 2004; Fernando et al., 2004) .
Most of these methods turn out to rank the genes in exactly the same order as the p-values which are driven by the perspective of the null hypothesis of no differential expression. Such methods implicitly assume that the most extreme p-values point to the biologically most relevant genes (von Heydebreck et al., 2004) . Bickel (2004) however recognizes that biologists often seek a minimum level of differential expression. Delongchamp et al. (2004) express the need to reliably eliminate the unaffected genes. They therefore not only examine the FDR but also its counterpart, the false non-discovery rate (FNR, Genovese and Wasserman, 2003) , and the fraction of genes not selected among the affected genes (FNS). They still however do not directly estimate nor control the number of truly (in)active genes that were missed in terms of a worthwhile alternative. Similarly, Taylor et al. (2004) introduce the 'miss rate' as a complement to the FDR. This is the proportion of non-null genes in a given interval below the rejection region. They find that a low FDR can accompany quite a high miss rate.
Problems with statistical power also occur in marker assisted selection (MAS). Hospital et al. (1997) recover power by allowing higher type I error rates and increase the significance level when heritability is low. Schön et al. (2004) call for further research about optimal type I error rates in view of the goals of plant breeders. Moerkerke et al. (2006) address this issue by incorporating a biologically relevant target alternative into a marker-specific decision criterion to balance the null and the alternative when selecting genetic markers for MAS.
In this paper, we develop the methodology for selecting genes focusing on a biologically relevant alternative. The key novelty of the approach is that the target effect, which is typically specified for power and sample size calculations, is directly involved in the decision criterion. To achieve this, we propose a measure of relative evidence against the null of no effect and the specified alternative, which ranks genes in terms of their corresponding promise. To decide on a cutoff point, we balance the classical p-value, p 0 , and its counterpart under the alternative, p 1 , by optimizing a weighted average of gene-specific type I and type II error rates resulting in a different rejection region for each gene. This procedure is called the balanced test. As gene-specific variances imply different levels of information, this gene-specific manner of optimization provides a ranking that can never be achieved by classical p 0 -values or test statistics. The strategy followed here aims to prevent researchers from finding only modest effects in a second phase because relevant signals were not picked up when screening all genes. As in Delongchamp et al. (2004) , we give user-specific weights to the null and the alternative, reflecting the relative cost of false positives and false negatives but although they emphasize the importance of FNS, their decision criteria are still based on p-value cutoffs.
We apply the new strategy to detect the genes that are differentially expressed between two types of breast cancer and study the corresponding experimentwise operating characteristics. This involves three levels of gene-expression: genes stemming from the null, those with an effect of at least the alternative and non-null genes situated in between.
Efron (2004) argues why we may indeed need to consider a whole distribution of null effects. We thus select a substantially different set of genes from those selected by more traditional methods and obtain a different ranking of these genes. We find that the genes selected reveal a more striking separation between the distribution of expression levels. In section 2, we present the data, introduce a measure of relative evidence against the null and the alternative and develop a formal two-sided testing procedure which incorporates p 1 , complement to the measure of significance. In section 3, the methodology is applied to the publicly available breast cancer data set of Hedenfalk et al. (2001) . We derive experimentwise operating characteristics in section 4 and compare our results with the more standard approach of controlling the FDR.
PROBLEM SETTING AND METHODOLOGY

Data
The search for genes associated with hereditary susceptibility to breast cancer has led to the identification of the BRCA1 and BRCA2 genes. Detecting genes that are differentially expressed between these types of tumors allows to discriminate between both cancers based on gene expression profiles and has the potential to further extend our understanding of gene expression of various cancer cells (Hedenfalk et al., 2001) .
In this paper, we develop methodology for powerful gene selection and analyze data on gene expression profiles of BRCA1-and BRCA2-mutation-positive tumors of Hedenfalk et al. (2001) also considered by Storey and Tibshirani (2003) . Data for 3 226 genes is available through 7 arrays with the BRCA1 mutation, 8 arrays with the BRCA2 mutation and 7 arrays of sporadic breast cancer. As in Storey and Tibshirani (2003) , we restrict the data to 3 170 genes that have no measurements exceeding 20, which is several interquartile ranges away from the interquartile range of all data. The sporadic breast cancer samples are not considered. Expression values are analyzed on the log 2 -scale. Information on the data is available on http://research.nhgri.nih.gov/microarray/NEJM_Supplement/.
We analyze the expression data to identify genes that are differentially expressed between BRCA1-and BRCA2-mutation-positive tumors using evidence against the null but also against a specified alternative.
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Notation
We adopt the following notation:
• ∆ j is the population contrast of interest between the outcome distributions F 1j and F 2j of gene j in the BRCA1 and BRCA2 group (j = 1, . . . , 3 170). In general, this may be a difference in means, a relative risk or a ratio of variances. We will consider the absolute difference in mean log 2 expression values between both tumor groups.
Hence, with µ kj the mean log 2 expression level of gene j and k = 1, 2 for the BRCA1 and BRCA2 group respectively, ∆ j = |µ 2j − µ 1j |.
• ∆ 1 is the predefined target magnitude for ∆ j we wish to detect.
• n 1 = 7 and n 2 = 8 are the number of arrays in the BRCA1 and BRCA2 group respectively.
• x klj is the expression value on the log 2 -scale of gene j in sample l in the BRCAk group (l = 1, . . . , n k ; k = 1, 2) with sample mean x kj = (1/n k ) n k l=1 x klj and sample variance s
2 . The corresponding population variance is denoted as σ 2 kj .
• fc j is defined as x 2j − x 1j , the observed fold change for each gene j.
Basic for the balanced test is the definition of a target alternative. In gene-expression studies, a twofold change, that is a mean difference of 1 in log 2 expression values (|fc j | = 1), is often considered of interest. Since original values are log 2 -transformed, this change implies a geometric means ratio of 2. We will target ∆ 1 = 1 for the true underlying effect ∆ j for each gene j (j = 1, . . . , 3 170).
http://biostats.bepress.com/harvardbiostat/paper39 2.3 An additional measure of significance As in Moerkerke et al. (2006) , we start by performing a one-sided test for∆ j = µ 2j −µ 1j of H 0j :∆ j = 0 versus H 1j :∆ j =∆ 1 > 0 for a given gene j with∆ 1 the target alternative. When outcomes are normally distributed in both tumor groups,
/n 1 the (known) standard error of the difference in sample means X 2j −X 1j (fold change), where |H kj ∼ indicates 'has conditional distribution given H kj '. We can derive p 0j = P (X 2j −X 1j > fc j |H 0j ) and p 1j = P (X 2j −X 1j ≤ fc j |H 1j ). p 0j represents the classical p-value calculated from the perspective of the null while p 1j is an alternative p-value for testing H 1j versus H 0j ; it is called a measure of impotence. Genes with small p 0j and large p 1j are of interest. The calculation of both types of p-values are depicted in Figure 1 . When performing multiple tests, the gene-specific standard errors will eventually lead to gene-specific rejection regions forX 2j −X 1j .
Figure 1 about here
To extend the methodology to a two-sided test of H 0j versus H 1j : |µ 2j − µ 1j | = ∆ 1 for each gene j, several considerations must be made. Corresponding p-values are
, the classical two-sided p-value for testing H 0j :
1j ), the p 1 -value for testing H
Unlike the traditional p 0 -value, the alternative p 1 -values are one-sided as they measure evidence against the given alternative in the direction of the null only. Ultimately, only 2 p-values per gene are useful: its p 0 -value and the maximum of p 1j> and p 1j< , which we call the p 1 -value, as the performed tests are two-sided. This means that p 1j is p 1j> when fc j > 0 and p 1j< otherwise.
In practice, we must allow for unknown variances in the computation of the p-values and given our small sample sizes (n 1 = 7 and n 2 = 8), we do not rely on distributional assumptions but use a permutation distribution as in Storey and Tibshirani (2003) . After permuting the group indicators for BRCA1 and BRCA2 over all samples we find a standard p 0j -value as the appropriate tail probability of the permutation distribution of
Under the alternative hypothesis H
are exchangeable and we permute them to obtain alternative p-values as corresponding tail probabilities of the test statistics
(2)
Technical details about deriving the permutation based p-values are given in appendix A.
Although the distributions of the test statistics T kj could be gene-specific, we pool the permutation distributions over all genes and use a common distribution to derive p-values for each gene (cfr. Storey and Tibshirani, 2003 for the distribution of (1)). In http://biostats.bepress.com/harvardbiostat/paper39
that way the distributions of (1), (2) and (3) become mixtures of all corresponding genespecific distributions. As in Taylor et al. (2004) , the distribution of T 0j can then be seen as the null distribution of a typical inactive gene. Following the same reasoning, the distributions of T 1j and T 2j are the null distributions of back transformed active genes with effect µ 2j − µ 1j = ∆ 1 and µ 1j − µ 2j = ∆ 1 , respectively.
Eyeballing the joint distribution of the (p 0 , p 1 )-values on a scatter plot helps to explore promising genes in an efficient and informative way. Through the joint measures we can avoid dismissing a possibly winning gene because of lack of convincing information in terms of the classical p 0 -value. The more traditional volcano plot shows significance versus the magnitude of the observed effect size (Jin et al., 2001) . Its effect measure does not account for imprecision however. p 0 ignores the target effect size but p 1 formally incorporates both.
The balanced test and a relative measure of evidence
The one-sided balanced test of Moerkerke et al. (2006) determines a gene-specific decision criterion by maximizing a gain function which is a weighted average of the genespecific type I and type II error rates:
where A j and B j represent the weights given to a correct decision under the null and the alternative, respectively. Consider first testing
170). Maximizing (4) or in this case
leads to the optimal cutoff c fc j for gene j on the scale of the fold change. The decision procedure for each gene j then becomes:
Accept H 0j if fc j ≤ c fc j and accept H
(1) 1j otherwise.
This decision criterion depends not only on ∆ 1 but as in to Delongchamps et al. (2004), also on the relative importance of the null and the alternative as expressed through the weight ratio A j /B j . In practice, A j /B j can be defined taking under consideration the (relative) costs of type I and type II errors and the odds of the null and the alternative.
If a study is conducted to rule out genes having not enough effect and to select a pool of promising genes, the focus will primarily be on the alternative and the ratio A j /B j will typically be less than 1. If only a few genes can be further investigated, protecting the null becomes more important resulting in a ratio larger than 1. Less prevalent alternative or null genes can possibly also influence the cost of false negatives or positives and hence the weight ratio. Defining ∆ 1 and A j /B j is inherent for any good study as it is equivalent with outlining the ultimate goals and corresponding cost analysis.
Once the gene-specific cutoffs c fc j are obtained, we use them not only to base the decision on but also to rank the genes according to a measure of relative evidence, the R-ratio (j = 1, . . . , 3 170):
is the p 0 -value corresponding to the one-sided test. (5) is then equivalent to:
The relative evidence measure positions the observed fold change with respect to the optimal cutoff through the ratio of (1 − p + 0j )/(1 − p 1j ) multiplied by a scale correction recognizing the different variance structures and rejection regions across genes. As a larger
) implies a smaller one-sided p 0 -value and/or a larger p 1 -value, a larger R j reflects more evidence against the null relative to the evidence against the alternative.
For two-sided tests, we adapt the one-sided test strategy. For genes with fc j = x 2j − x 1j > 0, the optimal cutoff and R-ratio for testing
1 > 0 is determined as described above implying that two-sided p 0 -values are replaced by the one-sided counterparts p + 0j , again calculated using the permutation distribution of (1). Likewise, the optimal cutoff and R-ratio for genes with fc j = x 2j −x 1j ≤ 0 are determined for testing
1j distributions of X 1j − X 2j are used and fc j is replaced by −fc j . The onesided p 0 -values are now p − 0j = P (X 1j − X 2j > −fc j |H 0j ). Computationally, the optimal cutoffs are obtained on the scale of the test statistics (1), (2) and (3) and are based on permutation distributions (see appendix B for further details).
Note that in a strictly one-sided testing framework A j /B j = 1 means that the null and the alternative are equally important implying equal probabilities of making a type I and type II error or α j = β j when testing gene j. By determining the cutoff in the same way for a two-sided test, we actually increase α j while keeping β j fixed. It follows that the choice A j /B j = 1 no longer gives equal weights to the null and alternative.
RESULTS
Descriptive analysis
The left hand side of Figure costs following a wrong decision. This is discussed in section 4 where we compare results following A j /B j = 10 and A j /B j = 1.
Here, we illustrate the qualitative and quantitative difference between our procedure and methods based on the classical p 0 -value. The q-value described in Storey and
Tibshirani (2003) Table 2 shows the p 0 -and p 1 -values, observed fold change and R-ratio for the top 10 genes based on the p 0 -rank versus the top 10 genes as ranked by the R-ratio which incorporates p 0 and p 1 . Our method does not only select a different subset of genes but also ranks these genes entirely differently. It is for instance striking that the gene with the smallest p 0 -value is ranked as number 137 due to its relatively small p 1 -value and absolute fold change. This illustrates that biologically relevant effects may not get a favorable ranking using p 0 -values when the observed effect is more variable. This difference in ranking is further elucidated in Figure 4 . Boxplots clearly show greater distance in distribution of expression values between both tumor groups for the top R-gene than for the top p 0 -gene. 
EXPERIMENTWISE OPERATING CHARACTERISTICS FOR THE BAL-ANCED TEST
As the balanced test optimizes a gain function for each separate gene, it does not directly protect a single predefined error measure as do other multiple testing procedures.
In this section, we estimate experimentwise error rates of the balanced procedure applied to the breast cancer data for two different weight ratios. We underline the different approach followed here, we define multiple testing measures of interest and compare the balanced test with the q-value approach. Although defining an effect of interest ∆ 1 should be rather straightforward, choosing an appropriate weight ratio A j /B j can be a challenge.
The approach in this section to estimate multiple testing measures of interest may also be used to construct an ROC-like curve for these measures corresponding to different weight ratios. 
Standard testing procedures focus on rejecting H S 0j or any non-null difference. As our main concern is to first and foremost detect effects of at least ∆ 1 and since genes under • TPR: the true positive rate estimated byt S /m 1S . Note that this corresponds to 1 minus the average type II error rate defined above.
• TNR: the true negative rate estimated as (v S +v B )/(m 0S + m 0B ).
• π T : the proportion of true targets estimated byt S /N .
• π B : the proportion truly below the target estimated as (v S +v B )/(m − N ).
• π T |O the proportion of the target alternative among the non-null features that are selected. This quantity is estimated by (t S )/(t S +f B ).
By putting more weight on the alternative or by lowering the cutoff for the relative evidence measure, more genes stemming from the alternative will be selected in trade off with a higher amount of false positives. The effect of the weight ratio is illustrated below.
Remember that a cutoff of 1 for R optimizes the gain function. Altering the weights will also change the order in which genes are selected while a different R-ratio cutoff would only change the number of genes selected but not the ordering.
In this section, we investigate the performance of the balanced procedure for A j /B j = 10 compared to A j /B j = 1. Data analysis follows several steps:
1. Choose the alternative ∆ 1 ; in our case ∆ 1 = 1.
2. Obtain a p 0 -value and p 1 -value for each gene.
Optimize a gene-specific gain function with weight ratio (null versus alternative)
A j /B j .
4. Calculate relative measures of evidence or R-ratios based on p-values in step 2 and optimal cutoffs from step 3.
5. Select genes with R j > 1. Both analyses are compared with two q-value strategies, one that selects a similar amount of genes and one with a comparable classical FDR (estimated asf S /N ).
Estimate P (H
Analysis 1:
We compare 3 different decision strategies: select a gene when
• its q-value is smaller than or equal to 0.10. 319 genes are selected and the estimated average type I error and type II error rate equal 0.015 and 0.27, respectively.
• its q-value is smaller than or equal to 0.15. This approach selects 511 genes with an estimated average type I and type II error rate of 0.036 and 0.18.
• the relative evidence measure is larger than 1 (with A j /B j = 10 for j = 1, . . . , m).
333 genes are selected with an estimated average type I and type II error rate of 0.023 and 0.19.
Results are in table 5 and 7. Slightly better than the first strategy with respect to π T and comparable with the second strategy with respect to π B , the balanced test scores convincingly better on π T |O . This results from gathering not only evidence against the null but also against the alternative.
In terms of the classical FDR and FNR derived from testing H
, our method is situated between the 2 q-value strategies. The FNR is estimated as (v B + w S )/(m −N ). The FDR's for the q-value approaches follow immediately from the decision criterion and are equal to 0.10 and 0.15. We obtain an estimated FDR of 0.145 for the balanced test. The estimates for the classical FNR are 0.28, 0.24 and 0.28 respectively for the 3 approaches. Both classical error rates are however of less interest for the approach followed here as false positives include also selected genes with an effect smaller than ∆ 1 and false negatives are only the genes with an effect of at least ∆ 1 that are not selected.
The main result that shows the discrepancy between the balanced test and procedures based on the ordering of classical p 0 -values is the detection of an expected amount of 136 alternative genes on a total of 333. Using the q-value approach, 511 genes need
Hosted by The Berkeley Electronic Press to be selected to obtain a similar result. One could argue however that our method with A j /B j = 10 selects a higher expected number of strict null genes than the q-value approach with q ≤ 0.10 (48.12 versus 31.38) while these genes are of no interest at all. But by doing that, we also select a higher expected number of true targets (136.09 versus 122.65) that we are directly aiming at. This is where the role of the weight ratio steps in: a different weight ratio would reflect a different trade-off. Moreover, the motivation for including the target effect is that genes stemming from the broad null are not the biologically relevant ones. Efron (2004) also addresses the choice of a null hypothesis and estimates a distribution of observed null and alternative effects. Performing many tests allows estimation of an empirical null hypothesis as it is in some cases not realistic to work under the strict null. These issues force us to rethink the definition of an appropriate alternative.
By incorporating the alternative directly in the decision criterion and making the decision criterion gene-specific, it is obvious that we score better than any method based on the classical p 0 -values. Shifting a p 0 -value cutoff will never achieve the same balance between true positives and true negatives.
Analysis 2:
• its q-value is smaller than or equal to 0.234. 834 genes are selected and the estimated average type I error and type II error rate equal 0.093 and 0.10, respectively.
• its q-value is smaller than or equal to 0.299. This approach selects 1 064 genes with an estimated average type I and type II error rate of 0.15 and 0.071.
• the relative evidence measure is larger than 1 (with A j /B j = 1 for j = 1, . . . , m).
834 genes are selected with an estimated average type I and type II error rate of 0.12 and 0.052.
Results are in table 6 and 7.
Table 6 about here Table 7 about here
As expected, a weight ratio with more weight on the alternative than in the first analysis results in a higher number of true targets that are selected in trade off with a higher number of false positives. Again, we find that the q-value approach needs to select a higher number of genes to achieve the same number of true alternatives which results in a higher false positive rate. The q-value approach that selects the same amount of genes has a smaller true positive rate. From this follows that our method is the most powerful to detect an effect of 1 while it achieves the smallest number of false positives (effects smaller than 1).
For the balanced test with A j /B j = 1, equal weights are given to the null and the alternative in the optimization procedure and this corresponds to an equal type I and type II error rate for each gene in the one-sided testing framework. This means R j > 1 is equivalent with selecting a gene when its corresponding one-sided p 0 -value (p + 0j for fc j > 0 and p − 0j otherwise) is smaller than its p 1 -value. However, we have performed the optimization numerically based on permutation distributions (appendix B) because this enables us to calculate type I and type II error rates. The results following numerical
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DISCUSSION
We have proposed a new selection procedure following analysis of the association between gene expression and phenotype, which balances evidence against the null with evidence against a specified alternative of interest. The methodology is more generally applicable in the context of selecting genes/genetic markers which play an important role in a trait of interest. The approach takes into account the (context-specific) relative importance of type I and type II errors and results in a relative evidence measure R (comparable with a likelihood ratio) according to which genes are ranked. An optimal cutoff for R then determines the selection region. Due to gene-specific variance structures as well as possibly gene-specific losses accompanying type I and type II errors, this entails a different nominal alpha and beta level per gene. As a result, the order in which genes are selected can differ dramatically from the standard p-value generated order. Marker-specific loss functions are also very natural in the marker assisted selection (MAS) context where a highly prevalent marker in the population, leaves little to gain by its introduction in the population. Investigation of performance measures can help to evaluate the weights given to the sharp null and alternative. In this particular data set, very few genes are expected to stem from the alternative, justifying (although not necessary or restrictive) a large weight on the null.
The idea that different null hypotheses are rejected at different significance levels to exploit varying levels of informativeness is not new. It is for instance reflected in the recent work of Wei and Uno (2005) , who control global coverage over many association analyses, when giving separate confidence intervals for different gene effects their own coverage level.
von Heydebreck et al. (2004) discuss moderated t-test statistics of Baldi and Long, 2001 , Tusher et al., 2001 , Lönnstedt and Speed, 2002 and Smyth, 2004 . These test statistics recover something of the fold change in the selection criterion by augmenting the genespecific variance estimator in the denominator by a constant to screen out statistically significant genes with small effects in absolute terms. We have estimated the variances based on relatively few samples. The empirical Bayes approach (see for example Lönnstedt and Speed, 2002 and Smyth, 2004 ) uses a weighted average of the gene-specific variance and the gene-specific variance for each gene. This may indeed be a good alternative to the procedure followed here.
Concerns about sacrificing power to optimize false discovery rates have also been addressed by Ishwaran and Rao (2003) and Lönnstedt and Speed (2002) . The BAM (Bayesian ANOVA for microarrays) technique of Ishwaran and Rao aims to strike a balance between between false rejections and false nonrejections. They consider posterior mean values and Bayesian model selection to assess differential expression. Lönnstedt and Speed motivate their Bayesian approach (B-statistic) by stating that there is in general a willigness to permit more false positives in order to avoid too many false negatives. More in particular, they handle a posterior odds of differential expression. We, on the other hand, incorporate the specified alternative as in classical power calculations, contrasting it with the sharp null of no effect.
While our criterion for selection is cast in terms of R and an optimality criterion, resulting experimentwise type I and type II error rates have been derived. Following our philosophy, false negatives are seen when effects at least as large as the target alternative remain undetected, and similarly false positive results select genes with a truly smaller effect. Corresponding rates have been estimated under a fixed alternative. The need to specify a target alternative was resolved quite easily in our application. This may be harder in other contexts, for instance when looking for gene-gene interactions. This warrants further research. Very recently, Norris et al. (2006) also consider balanced testing in which they propose to give penalties to false positives and negatives. Contrary to our philosophy, their main concern is that standard FDR controlling procedures often fail to pick up modest effects. Basic differences with our balanced test is their ranking of genes according to classical t-test statistics and the fact that statistical power is defined using the underlying distribution of alternative genes in the study.
We have taken the popular approach of considering one gene at a time, ignoring correlations. As more biological knowledge becomes available, modeling the joint distribution of gene expression becomes feasible. Decision criteria built on this could be adjusted in line with the balanced test for the genes separately to capture a fold change of interest.
In summary we believe the proposed procedure has great promise in providing a semi-automatic selection procedure allowing to screen many genes for their potential impact on phenotype. It makes particular sense to put much greater emphasis on type II error in a first screening round and concentrate more on type I errors later. The ability to balance the power to detect important alternatives with significance at the selection level meets the need of many researchers. We hope to have provided a useful procedure which has this direct focus.
APPENDIX A. PERMUTATION BASED P -VALUES
The classical two-sided p-value for each gene j (j = 1, . . . , 3 170) equals
where the distribution of T 0j under H 0j is obtained using permutations and t 0j is the observed test statistic in (1). In total 100 permutations (b = 1, . . . , 100) are performed by randomly permuting the labels of the tumor groups. In each permutation step, the 3 170 t-test statistics t 0j are re-computed constructing a non-parametric null distribution for each gene conditional on the observed data. The p 0 -values are then calculated using the distribution of T 0j constructed by these null statistics over all genes (100 × 3 170 in total):
100 × 3 170 with t b 0i the permutation based t-test statistic t 0i for gene i in permutation step b. This implies that a global null distribution is considered for all genes.
The alternative p 1 -values of interest are
where the distribution of T 1j under H (1) 1j and of T 2j under H (2) 1j is again obtained using permutations and t 1j and t 2j are the observed test statistics in (2) and (3), respectively.
The distribution of T 1j (T 2j ) is constructed by first subtracting ∆ 1 from each expression level in the BRCA2 (BRCA1) group and by randomly permuting the labels of the tumor groups afterwards. Under the hypothesis that µ 2j − µ 1j = ∆ 1 (µ 1j − µ 2j = ∆ 1 ) for j = 1, . . . , 3 170, there is no differential gene expression anymore when subtracting ∆ 1 from the observed expression levels in the BRCA2 (BRCA1) group. Hence, the t-test statistic t 0j (−t 0j ) in (1) calculated based on these transformed data after subtracting ∆ 1 , which we refer to as t * 0j (t * * 0j ), should follow the same distribution regardless of how the group assignments are made. Therefore, the alternative p 1 -values are obtained as follows:
100 × 3 170
with t * b 0i (t * * b 0i ) the permutation based t-test statistic t * 0i (t * * 0i ) for gene i in permutation step b. It follows that global alternative distributions are considered for all genes. Note that t * 0j (t * * 0j ) based on the unpermuted data equals t 1j (t 2j ). To determine the distribution of T 1j (T 2j ), ∆ 1 has to be subtracted first since group labels then become exchangeable. If labels are permuted and then a permutation based t 1j (t 2j ) in (2) ( (3)) is calculated, we
will not obtain the appropriate distribution.
APPENDIX B. DETERMINING OPTIMAL CUTOFFS FOR THE BAL-ANCED TEST
As we are interested in testing a two-sided alternative hypothesis for each gene, we introduce the following notation:
∆ Aj = µ 2j − µ 1j and a = 1 when fc j > 0, ∆ Aj = µ 1j − µ 2j and a = 2 otherwise, (j = 1, . . . , 3 170).
For each gene j, we test:
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The final decision criterion is expressed in terms of a cutoff on the scale of the t-test statistics. This optimal cutoff is determined by optimizing
with I fc j = 1, T Aj = T 1j when fc j > 0 and I fc j = −1, T Aj = T 2j otherwise. The type II error rate implied by the rejection region for gene j is calculated similarly to the p 1 -value for c + j but accounting for the fact that the performed tests are two-sided. The type I error rate is found as the p 0 -value for c j . Of course, the criterion I fc j × T 0j > c j is equivalent to T Aj > c + j . The separate notation is only introduced to stress the different scales we are working under (i.e. the null and the alternative).
Optimal cutoffs can be found numerically based on the permutation distributions of T 0j , T 1j and T 2j . For some genes, cutoffs are rather large while very little improvement in expected gain (4) is actually obtained. In such cases, we choose a smaller cutoff for which the expected gain is very close to the maximum. In this application A j /B j = 10 and the expected gain in (4) is rescaled on a range from 0 to 1 by choosing A j = 10/11 and B j = 1/11. In this way, distances are measured on the same scale for all genes. In the second analysis with A j /B j = 1, A j = B j = 1/2.
APPENDIX C. OPERATING CHARACTERISTICS FOR THE BALANCED TEST
C.1. Prevalence of the worthwhile alternative
The estimate for P (H S 0j ) equals 0.66 and is obtained based on the classical p 0 -values with the algorithm described in Storey and Tibshirani (2003 ). This aspect is the subject of further research. Neither situation seems to be the case here. The histogram density is fairly flat beyond 0.6 and no peak around 1 emerges. The height of this portion is an estimate for the proportion of genes stemming from the alternative. We find that 0.053 seems a reasonable estimate. 
where α j represents the significance level for the test for gene j (j = 1, . . . , m).
(6) is estimated as the average significance level over all m genes since
with I H 0j = 1 if H S 0j is true for gene j. Withπ 0 an estimator for P (H S 0j ), (6) can therefore be estimated as
The CWER α j for each gene j is calculated as the p 0 -value of the optimal cutoff based on the permutation distribution of T 0j which is the permutation distribution of the test statistics under H S 0j . The estimated average type I error rate for the balanced test is 0.023 for A j /B j = 10 and 0.12 for A j /B j = 1.
If a single p 0 -value cutoff is used for all genes, this cutoff is the average type I error rate. The criterion to select all genes with a q-value lower or equal to 0.10 corresponds to a p 0 -value cutoff of 0.015 and a q-value cutoff of 0.15, 0.234 and 0.299 to a p 0 -value cutoff of 0.036, 0.093 and 0.15 respectively. For the balanced test, the type II error rate is based on the optimal cutoff for each gene. For the q-value approaches, the same cutoff is used for all m genes but as the type II error rate also involves the variance structure of the genes, a different type II error rate is obtained for each gene. For the first analysis in section 4, the estimated average type II error rate for the balanced test equals 0.19, 0.27 for the q ≤ 0.10-approach and 0.18 for the q ≤ 0.15-approach. For the second analysis, these 3 rates are 0.052, 0.10 and 0.071 respectively. Tables   Table 1: Crosstab comparing the balanced test (A j /B j = 10) and q-value approach q j ≤ 0.10 q j > 0.10 Total 
C.3. Average type II error rate
When testing H
S 1j : |µ 2j − µ 1j | = ∆ j = ∆ 1 against H B 0j : |µ 2j − µ 1j | = ∆ j < ∆ 1 forR j > 1
